ARVN
Arvinas, Inc.
NasdaqGSUSDEQUITY
DELAYED
Last price
9.37
▲ 0.34 (3.77%)
MARKET · —
Price
Open
8.91
Prev close
9.03
Day high
9.38
Day low
9.00
Volume
879.66K
Market cap
—
P/E (TTM)
—
52W range
6.97 – 14.51
Trailing performance
Returnvs SPY
1W
+4.46%
+5.8%
1M
+15.39%
+11.7%
3M
+2.97%
-0.1%
6M
-21.85%
-32.9%
YTD
-20.99%
-33.3%
1Y
+31.97%
+12.0%
3Y
-61.41%
-135.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
9.14
+2.50% from price
SMA 20
8.76
+6.95% from price
SMA 50
8.34
+12.33% from price
SMA 100
9.04
+3.55% from price
SMA 200
10.59
-11.55% from price
EMA 12
9.06
+3.38% from price
EMA 26
8.78
+6.68% from price
EMA 50
8.71
+7.52% from price
RSI (14)
60.2
Neutral
MACD (12,26,9)
0.28
Hist 0.06
ATR (14)
0.48
5.10% of price
Realised vol 30D
52.2%
Annualised
Bollinger upper
9.69
20, 2σ
Bollinger lower
7.84
20, 2σ
50 / 200 cross
Death
8.34 vs 10.59
Trend bias
Below 200
-11.55%
Risk profile
Beta vs SPY
1.13
More volatile than market
Correlation to SPY
0.27
Largely independent
Realised vol 30D
52.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-49.5%
Peak to trough
Max drawdown 5Y
-93.7%
Peak to trough
ATR 14
0.48
5.10% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Arvinas (ARVN) Q2 2026 Earnings Call Transcript
Motley Fool · 11d ago
Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says
MT Newswires · 12d ago
Morgan Stanley Adjusts Price Target on Arvinas to $10 From $11, Maintains Equalweight Rating
MT Newswires · 12d ago
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
Zacks · 16d ago
Arvinas, Inc. Q2 2026 Earnings Call Summary
Moby · 18d ago
Wedbush Adjusts Price Target on Arvinas to $12 From $11, Maintains Neutral Rating
MT Newswires · 18d ago
Arvinas Q2 Earnings Call Highlights
MarketBeat · 18d ago
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
Zacks · 18d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.